Professor Thomas Kietzmann's team in Oulu just upended everything we thought we knew about an everyday anemia medication—and in doing so, they may have handed cancer patients an unexpected gift. In a new study published in Redox Biology, researchers from the University of Oulu and the University of Eastern Finland discovered that HIF-PHIs, drugs long used to help patients with chronic kidney disease produce more red blood cells, possess a hidden superpower: they can slow cancer cell growth through mechanisms that have nothing to do with their primary job.
This matters profoundly because many cancer patients face a brutal double burden. Tumors and chemotherapy both cause anemia, leaving patients weakened and struggling. Today, treating the anemia and fighting the cancer are two separate medical battles. But what if a single medication could target both?
The research reveals something striking. HIF-PHIs work by stabilizing proteins that help cells respond to low oxygen levels—that's their known function for anemia patients. Yet when Kietzmann's team investigated deeper, they found something unexpected: the drugs also influence cell growth and blood vessel formation even when those oxygen-sensing proteins aren't involved. "We expected the drugs to work only through the usual oxygen pathway," Kietzmann explains. "Instead, we saw that they could stop cells from growing and prevent new blood vessels from forming on their own. This changes how we understand what these drugs do in the body."
The implications ripple outward immediately. Since HIF-PHIs are already approved medications with established safety profiles, they could potentially be combined with classical chemotherapy to address both problems at once. Rather than sequential treatments for anemia and cancer, patients might benefit from a coordinated approach where one drug tackles two targets simultaneously. For someone already enduring the burden of cancer treatment, the prospect of efficiency matters enormously—both medically and emotionally.
Yet the researchers are careful not to overstate their findings. This is laboratory research, groundbreaking but preliminary. To move from the bench to the clinic, they need clinical partners willing to test these discoveries in actual patients. Kietzmann is explicit about what comes next: "We have the mechanistic data, but now we need the clinical expertise to move forward. We encourage oncologists and clinicians interested in tumor anemia to collaborate with us. Initiating clinical trials could reveal a dual advantage for patients."
That call for collaboration is a reminder that scientific breakthroughs rarely happen in isolation. The researchers in Finland have mapped new territory. Now they need the oncologists, hematologists, and clinical trial specialists who work directly with patients to help them navigate it. It's the kind of bridge-building that transforms laboratory promise into lived reality.
For cancer patients dealing with both tumors and anemia, the road ahead remains uncertain. But this research suggests it doesn't have to be quite so arduous. A medication that fights cancer while simultaneously restoring strength and red blood cells would represent not just a scientific advance, but a shift in how we think about treatment itself—combining forces rather than fighting separate battles.